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Abstract Tumours, which are initially sensitive to cytotoxic
agents, often develop resistance to a broad spectrum of structur-
ally unrelated drugs. The 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase inhibitors have been shown to inhibit
ATP-binding cassette (ABC) transporters but have also impact
on glycosylation of such proteins. Doxorubicin is a substrate for
ABC transporters like P-glycoprotein (ABCB1) which is present
in human RD rhabdomyosarcoma cells. It was therefore the aim
of this study to identify the compartmentalisation and action of
doxorubicin in simvastatin-treated RD cells. Due to autofluores-
cence of doxorubicin, intracellular distribution was monitored by
confocal microscopy. The biological effects were traced on the
level of colony formation, caspase activation and DNA injury.
Here we show that simvastatin treatment leads to ABCB1 inhi-
bition and down-regulation of the transporter. Consequently,
these cells accumulate significant amounts of doxorubicin, pre-
dominantly in the nucleus and lysosomes.While clearance of the
anthracycline into lysosomes is not altered by simvastatin treat-
ment, it significantly enhanced nuclear accumulation in a HMG-
CoA reductase-independent manner. Thus, in such treated cells,
topoisomerase II activity is significantly inhibited, which is fur-
ther corroborated by augmented double-strand DNA breaks.
Moreover, colony formation was synergistically inhibited by
the combination of simvastatin and doxorubicin. Given the fact
that ABCB1 expression correlates with an adverse prognosis in
many tumours, adjuvant chemotherapy including statins might
represent a novel therapeutic concept to overcome ABCB1-
mediated multidrug resistance by direct inhibition and down-
regulation.
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Abbreviations
ABC transporter ATP-binding cassette transporters
ABCB1 ABC transporter B1, P-glycoprotein
AFC 7-Amino-4-trifluoro-methylcoumarin
ANOVA Analysis of variance
DMEM Dulbecco’s modified Eagle medium




RIPA buffer Radio immunoprecipitation assay
buffer
Introduction
Rhabdomyosarcoma is the most common soft tissue
sarcoma of childhood, accounting for more than half
of such cases in paediatric patients (Raney et al.
1993). Initial treatment is often successful, but relapses
due to multidrug resistance (MDR) remain a major
obstacle to survival. Thus, the overall outcome in
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paediatric rhabdomyosarcoma is therefore still a thera-
peutic challenge. In part, MDR may be caused by
changes in the expression level or activity of ATP-
binding cassette (ABC) transporters (Endicott and Ling
1989; Liscovitch and Lavie 2002; Szakacs et al. 2006).
Ways of reversing MDR via ABC transporters have been
investigated extensively in recent years, and three genera-
tions of inhibitors have been developed (Liscovitch and
Lavie 2002; Szakacs et al. 2006). Among these, verapamil,
cyclosporine A and tariquidar have emerged as lead com-
pounds for characterisation in vitro. Nevertheless, due to
severe side effects, such as nephrotoxicity for cyclosporin A
or cardiac toxicity for verapamil, these MDR modulators
failed to convince in clinical trials (Cocker et al. 2000;
Szakacs et al. 2006). Although there are many new MDR-
modulating agents available for in vitro usage, no effective
and clinically applicable therapy has yet evolved (Liscovitch
and Lavie 2002; Szakacs et al. 2006; Tamaki et al. 2011).
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors, commonly referred to as statins,
are widely used in hypercholesterolaemia and prevent car-
diovascular events (Lennernas and Fager 1997; Corsini et al.
1999; Group 2000). In recent years, evidence emerged that
anti-inflammatory and anti-proliferative actions of statins
also contribute to beneficial cardiovascular outcomes. These
effects have led to a series of in vitro studies which came to
the conclusion that statins also exert anti-tumour activity
which has been targeted to cell cycle arrest, depletion of
cholesterol precursors like isoprenoids and oxidative stress
(Demierre et al. 2005; Sleijfer et al. 2005). However, in
clinical studies, the role of statins in oncology is still con-
troversial and seems to be strongly dependent on the mo-
lecular identity of the tumour (Graaf et al. 2004; Poynter et
al. 2005; Nielsen et al. 2012).
Statins are capable to inhibit the rhodamine 123 efflux
from tumour cells via their lactone form but not in the
hydrolysed acidic form (Bogman et al. 2001). Such inhibi-
tion of efflux activity could be attributed to ABCB1 inter-
action with statins (Wang et al. 2001; Sakaeda et al. 2002;
Chen et al. 2005). In a previous work, we made similar
observations and could show that glycosylation of ABCB1
is reduced in simvastatin-treated human neuroblastoma cells
(Sieczkowski et al. 2010). The mutual enhancement of
cytotoxicity between statins and doxorubicin has been
shown in neuroblastoma cells and RD rhabdomyosarcoma
cells to trigger the mitochondrial apoptotic machinery
(Werner et al. 2004; Sieczkowski et al. 2010). Since statins
are capable to trigger caspase activity per se, it is difficult to
estimate the apoptotic potential of doxorubicin in drug com-
binations. Moreover, it is unclear whether enhanced intracel-
lular doxorubicin accumulation is targeted to individual
organelles and whether this translates into specific
doxorubicin-mediated cytotoxicity. However, one would
postulate that enhanced intracellular doxorubicin concentra-
tions might translate into augmented topoisomerase II
inhibition.
Thus, it was the aim of the present work to confirm
synergism between simvastatin and doxorubicin. Moreover,
intracellular compartmentalisation of doxorubicin and func-
tional implications thereof were investigated.
Materials and methods
Materials
Dulbecco’s modified Eagle medium (DMEM) was pur-
chased from Gibco® (Invitrogen®, Paisley, Scotland,
UK). Doxorubicin, daunorubicin, rhodamine 123, prote-
ase inhibitors (pefablock, leupeptin and aprotinin), soft
agar and other common chemicals were from Sigma
Chemical Co.® (St. Louis, MO, USA). Simvastatin and
verapamil were purchased from Merck® Research Labo-
ratories (Rahway, NJ, USA). Concanamycin A and fluo-
rescent substrates for caspases 3 and 8 were from
Alexis Biochemicals® (San Diego, CA, USA).
Lysotracker® Red was obtained from Molecular Probes®
(Eugene, OR, USA).
Cell culture
Human rhabdomyosarcoma cells (RD cells) of the spindle
cell type were obtained from ATCC® (Manassas, VA, USA)
and kept in growth medium (DMEM, 10 % foetal calf
serum, 50 U/ml penicillin G and 50 μg/ml streptomycin)
at 37 °C under 5 % CO2 for 2–5 days prior to experiments.
The CCRFvcr1000 cells were cultured as previously de-
scribed (Chiba et al. 1996; Hiessbock et al. 1999) and used
to confirm simvastatin as inhibitor of ABCB1.
Caspase assays
RD cells were incubated with simvastatin, doxorubicin
and/or mevalonic acid for the indicated times and concen-
trations. Thereafter, the cells were lysed (lysis buffer—
25 mM HEPES (pH 7.4), 5 mM EDTA, 1 mM EGTA,
5 mM MgCl2, 5 mM DTT, supplemented with protease
inhibitors 1.4 μg/ml aprotinin, 10 μg/ml leupeptin and
100 μM pefablock) and centrifuged (35,000×g, 30 min),
and aliquots of the supernatant were used for a fluorescence-
based caspase assay (reaction buffer—25 mM HEPES
pH 7.4, 10 % sucrose, 1.4 mM CHAPS and 5 mM DTT
and 50 μM AFC-conjugated caspase substrates) (Werner et
al. 2004). The corresponding pellet is termed “membrane
fraction”, resuspended in radio immunoprecipitation assay
(RIPA) buffer and further used for Western blotting.
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Topoisomerase II decatenation assay and histone H2AX
phosphorylation
RD cells (5×107 cells) were treated with drugs according to
the figure legends for 24 h. The cells were lysed and
processed for nuclear extraction according to Dansk et al.
(1988). Nuclear extracts (20 μg) were assayed for topoisom-
erase II activity (30 min at 37 °C) using a topoisomerase II
decatenation kit (Inspiralis®, Norwich, UK). The reaction
was terminated with 2.5 % SDS and the DNA separated on
a 1% agarose gel. Densiometric analysis was carried out using
the ImageJ® software (http://rsbweb.nih.gov/ij/index.html).
Alternatively, the phosphorylation of histone H2AX was
used as a sensitive measure for double-strand DNA breaks.
A flow cytometry based histone H2AX phosphorylation kit
was used (Millipore®, Temecula, CA, USA). RD cells were
treated as depicted in the figure legend and further processed
and stained with an FITC-conjugated antibody specific for
serine139 phosphorylation of histone H2AX according to
the instructions of the manual. The positive stained cells
were quantified by flow cytometry. The fluorescence sig-
nal in the absence of the antibody was used as a
negative control and RD cells treated with 10 μM
etoposide as a positive control.
Western blot analysis
Aliquots of membrane fractions (15 μg) from RD cells
resuspended in RIPA buffer were applied to an 8 %
sodium dodecyl sulphate polyacrylamide gel. The sepa-
rated proteins were transferred to nitrocellulose mem-
branes (Watman®, Dassel, Germany) and exposed to an
ABCB1-specific primary antibody (C219 mouse mono-
clonal P-gp antibody, Abcam®, Cambridge, UK; diluted
at 1:300) for 90 min at room temperature. Specific
bands were visualised with an appropriate horse radish
peroxidase-conjugated secondary antibody (anti-mouse
IgG, horseradish peroxidase-linked antibody, GE
Healthcare®, Bucks, UK; diluted 1:15,000, 60 min at
room temperature) using an ECL Plus detection system
(GE Healthcare®, Bucks, UK). Immunodetection of α-
tubulin (monoclonal anti-α-tubulin; Sigma®; St. Louis,
USA; dilution of 1:7,500) was used to control protein
loading.
Colony forming assay
Trypsinised RD cells were seeded in 6- and 12-well plates at
a density of 500 cells per well, precoated with 0.5 % soft
agar. After 24 h, cells were incubated in the absence and
presence of doxorubicin, simvastatin or a combination of
both at the given concentrations. After 15 days, the cells
were fixed with 50 % ethanol and stained with 0.5 %
methylene blue. Cell growth was evaluated by counting
colonies with more than 50 cells.
Fluorescence-activated cell sorting (FACS) analysis
RD cells were treated with simvastatin or verapamil for
10 min and subsequently with doxorubicin for further
60 min. Cells were analysed for doxorubicin accumulation
on a FACScan (Beckton Dickinson®, New York, USA) with
an excitation of 488 nm and an emission filter of 600 nm.
For histone H2AX phosphorylation, RD cells were exposed
to the indicated compounds for 18 h and treated according to
the kit instructions. The FITC-conjugated antibody against
histone H2AX phosphorylation was detected with an excitation
at 488 nm and an emission at 515 nm. A total of 104 cells were
counted per sample and the data were processed using
WinMDI software® (http://www.cyto.purdue.edu/
flowcyt/software/Winmdi.htm) or FACSDiva® (BD Bio-
sciences®, San Jose, CA, USA).
Confocal fluorescence microscopy
RD cells were grown on glass cover slides and incubat-
ed for 18 h in the absence or presence of simvastatin,
verapamil or concanamycin A for 1 h. Such treated
cells were subsequently exposed to 1 μM doxorubicin
for an additional hour. Cells were washed with PBS and
supplied with fresh culture medium. Images were col-
lected using a confocal microscope (Zeiss® LSM 410;
Jena, Germany), an excitation of 488 nm and an emis-
sion of 543 nm for LysoTracker® Red (Molecular
Probes®, Leiden, Netherlands) or 570 nm for doxorubi-
cin. The digitised pictures from a single focal plane
containing two to six cells were stored. The doxorubicin
intensity was measured in the nucleus (55–69 cells) and
lysosomes (91–296 cells) using MetaMorph® software
(Universal Imaging Corporation, Downington, PA,
USA) and ImageJ® software (http://rsweb.nuh.gov/ij).
For the doxorubicin co-localisation in the lysosomes,
cells were pre-incubated in the culture medium with
10 μM simvastatin and 15 μM verapamil for 1 h and another
hour together with 1 μM doxorubicin. Pictures of doxoru-
bicin autofluorescence were obtained as described above.
Subsequently, 20 nM LysoTracker® Red was added and the
fluorescence signal collected.
The kinetic analysis of nuclear accumulation of doxo-
rubicin was carried out under conditions described
above with minor changes. RD cells were incubated
for 20 min in the absence and presence of simvastatin
or the combination of simvastatin plus mevalonic acid.
Immediately after the doxorubicin addition, a series of
pictures was taken for the indicated period with the
settings described above.
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Daunorubicin, rhodamine 123 and cacein flux
measurements
CCRFvcr1000 cells were pre-treated with various concen-
trations of simvastatin or 15 μM verapamil for 20 min.
Daunorubicin and rhodamine 123 were used as transporter
substrates as previously reported (Chiba et al. 1996;
Hiessbock et al. 1999). The IC50 values for simvastatin were
determined in zero trans efflux and steady-state protocols. In
the steady-state protocol, apparent IC50 values were
corrected for differences in ABCB1 expression considering
a pump-leak situation.
For calcein efflux measurements, RD cells were pre-
treated with various concentrations of simvastatin or
15 μM verapamil for 20 min or 48 h. Cells were gently
detached and 5×105 cells were resuspended in HEPES/Na-
Puffer (20 mM HEPES, 132 mM NaCl, 3.5 mM KCl, 1 mM
CaCl2, 0.5 mM MgCl2, 5 mM glucose) supplemented with
the respective drugs from the 20-min pre-incubation. No
drugs were supplemented to cell suspensions from the 48-
h pre-treatment. The experiment was started with 1 μM
calcein-AM uptake and reaching a plateau. After 30 min,
the extracellular calcein was quenched by 1 mM of CoCl2.
The fluorescence was monitored at an excitation wavelength
at 485 nm and an emission at 535 nm using a fluorescence
plate reader (VICTOR-3, Perkin-Elmer®, MA, USA) with
sampling rates of 10 and 30 s or 3 min, depending on the
phase of the experiment (calcein efflux, calcein-AM uptake
or plateau phase, respectively).
Miscellaneous procedures
Experiments were carried out at least three times in
duplicates and presented as mean ± SD, if not otherwise
stated. The curves were subjected to non-linear least
squares regression and fitted to the according equations
(Hill equation) using the Sigmaplot® software (Jandl,
Erkrath, Germany). Statistical analysis was carried out
by Student’s t test or for multiple comparisons by
ANOVA and post hoc Dunnett’s test (when compared
to control) or Tukey’s test (for pairwise comparison). A
value of p<0.05 was considered statistically significant.
Results
Simvastatin and doxorubicin synergistically activate
the mitochondrial pathway of apoptosis
In human RD cells, HMG-CoA reductase inhibitors like
simvastatin readily activate the effector caspase 3 in a
concentration-dependent manner (Fig. 1a). The EC50 of
simvastatin-induced caspase 3 activation shifted by more
Fig. 1 Potentiation of caspase 3 activity by simvastatin plus doxoru-
bicin. RD cells were grown in the absence and presence of simvastatin
(sim), doxorubicin (dox) and mevalonic acid (ma, 1 mM) at the given
concentrations for 24 h. Aliquots of the supernatant of lysed cells were
used for caspase 3 (a, c) and caspase 8 activity (b). The data are given
as mean values ± SD (n=4). Statistical significance was determined
with ANOVA and post hoc Tukey’s test (asterisk denotes significance
versus control *p=0.039, **p<0.001; number sign denotes signifi-
cance versus sim ##p<0.001; plus sign denotes significance versus
sim+dox ++p<0.001; n.s. not significant)
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than one order of magnitude from 9.9±1.2 to 0.69±0.2 μM
(mean ± SD, n=4; p<0.001) upon co-application with doxo-
rubicin at a clinically relevant concentration (Lee et al.
1980). Under these conditions, caspase 8 was not signifi-
cantly activated, neither by simvastatin alone nor by a
combination with doxorubicin (Fig. 1b). The simvastatin-
induced caspase activation is strongly dependent on HMG-
CoA reductase inhibition and thus prevented by co-
application with mevalonic acid (Werner et al. 2004;
Minichsdorfer and Hohenegger 2009; Sieczkowski et al.
2010). In contrast, doxorubicin-induced caspase 3 activation
is insensitive to co-administration of mevalonic acid
(Fig. 1c). However, a more than additive stimulation of
caspase 3 is seen with the co-administration of doxorubicin
and simvastatin. This is significantly reduced by mevalonic
acid to the level of doxorubicin alone. Thus, the mutual
sensitisation for apoptosis is only seen for the intrinsic
pathway of apoptosis, which has been previously depicted
for statins in more detail (Werner et al. 2004). These results
confirm that simvastatin potentiates doxorubicin toxicity
in RD cells at concentrations that have been well toler-
ated in patients receiving simvastatin (Lennernas and
Fager 1997; Larner et al. 1998).
Synergistic inhibition of colony formation by simvastatin
and doxorubicin
HMG-CoA reductase inhibitors have been shown to synchro-
nise tumour cells by blocking the transition of G1–S in the cell
cycle, which explains their anti-proliferative effects in many
cell types (Rao et al. 1999; Dimitroulakos et al. 2001;
Ukomadu and Dutta 2003). We have therefore investigated
colony formation of RD cells in the presence of increasing
concentrations of simvastatin and doxorubicin, exemplified in
Fig. 2a. In fact, RD cells are highly susceptible to inhibition of
colony formation with an IC50 of 3.42±0.7 nM doxorubicin
(mean ± SD; n=3) (data not shown). Consistent with our
previous observations on caspase 3 and 9 activation, the
efficacy to suppress colony formation is more pronounced in
the combination of simvastatin and doxorubicin as compared
to the individual compounds (Fig. 2a) (Werner et al. 2004).
The potency of the individual compounds to prevent colony
formation is not influenced by the presence of the second
compound as depicted in Fig. 2a (IC50 for simvastatin 3.0±
1.3 μM versus simvastatin plus 5 nM doxorubicin 2.8±
2.1 μM; mean ± SD, n=3). The isobologram analysis revealed
a clear synergistic interaction for the drug combination of
simvastatin with doxorubicin (Fig. 2b).
Inhibition and down-regulation of ABCB1 by simvastatin
Taking advantage of the fluorescence properties of doxoru-
bicin, a short pre-treatment of RD cells with simvastatin
resulted in a significant increase in doxorubicin fluorescence
as monitored by FACS analysis (Fig. 3a, b). Similarly, the
first generation ABCB1 inhibitor verapamil also enhanced
the intracellular accumulation of doxorubicin. In a control
experiment without doxorubicin, autofluorescence of the
cells in the absence or presence of simvastatin was not
observed (data not shown).
There are already reports that statins are capable of
inhibiting ABC transporters (Bogman et al. 2001; Wang et
Fig. 2 Synergistic inhibition of colony formation by simvastatin and
doxorubicin. Aliquots of 500 RD cells were seeded in 12-well plates,
and after 24 h, cells were incubated with the indicated doxorubicin and
simvastatin concentrations (a). After 15 days, colonies of more than 50
cells were counted. The data are given as mean ± SEM (n=3). The
fractional inhibitory concentrations (FIC) of various combinations of
simvastatin and doxorubicin were blotted in an isobologram (b). The
solid line indicates additivity. The experimental data points were cal-
culated from experiments as described in (a) and confirm synergism
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al. 2001; Sakaeda et al. 2002; Sieczkowski et al. 2010). We
have therefore investigated the effects of simvastatin on
ABCB1 in greater detail in CCRFvcr1000 cells, which
express a defined number of transporter molecules (Chiba
et al. 1996; Hiessbock et al. 1999). Such an approach en-
ables to normalise the transporter activity to the actual
number of transporters in the cells. Using this experimental
approach, first-order rate constants of daunorubicin and
rhodamine 123 efflux show a clear inhibition by simvastatin
with IC50 values of 4.6±1.6 and 49.3±4.7 μM (mean ± SD;
n=3), respectively (Fig. 4). The Hill coefficient between 1.1
and 1.2 in both cases is indicative for a non-cooperative
interaction. Comparable results were obtained when verap-
amil was used as a P-glycoprotein inhibitor which gave IC50
values in the same concentration range (Chiba et al. 1996;
Hiessbock et al. 1999). In order to further corroborate this
assumption, calcein efflux was determined in RD cells
Fig. 3 Enhanced intracellular doxorubicin content in the presence of
simvastatin or verapamil. Doxorubicin accumulation was assessed with
flow cytometry in RD cells treated for 1 h with 1 μM doxorubicin (ctl)
(a). Preincubation of the cells for 10 min with 3 μM (sim3), 10 μM
(sim10) simvastatin or 15 μM verapamil (ver) enhanced the doxorubi-
cin fluorescence intensity. The experiment was repeated twice with
similar results. The mean increase in doxorubicin fluorescence under
conditions given in a is depicted in the bar diagram (b). The data were
processed with WinMDI software and presented as geometrical mean ±
SD (n=3)
Fig. 4 Simvastatin inhibits ABCB1 in CCRFvcr100 cells. The
ABCB1 expressing CCRFvcr100 cells were loaded with daunorubicin
(a) or rhodamine 123 (b) and the kinetics of the decrease in fluores-
cence was determined in the presence of increasing concentrations of
simvastatin. The calculated first-order rate constants (Vmax/Km) were
blotted in these concentration–response relationships. The symbols
represent the mean ± SD (n=3)
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(Fig. 5). The calcein efflux is best described by fitting the
data points to a biexponential decay. Thus, the two half lives
of calcein efflux were significantly prolonged already in the
presence of 1 μM simvastatin (Fig. 5b, c).
ABCB1 is present in RD cells and, importantly, is down-
regulated upon incubation for 48 h with increasing concen-
trations of simvastatin (Fig. 6a, b). Thus, these observations
corroborate and expand earlier observations of our labora-
tory in human neuroblastoma cells that deglycosylation
might impair not only the function of ABCB1 but also
protein expression (Sieczkowski et al. 2010). To confirm a
functional consequence, such treated RD cells were washed
and subjected to calcein efflux measurements, and again, a
significant prolongation of the half lives was observed.
Hence, a direct inhibition of ABCB1 by simvastatin is in
accordance to earlier observations and is now expanded by a
significant down-regulation of the transporter (Bogman et
al. 2001; Wang et al. 2001; Sakaeda et al. 2002;
Sieczkowski et al. 2010).
Mining intracellular doxorubicin accumulation under
simvastatin treatment
In order to further trace intracellular doxorubicin accumula-
tion, RD cells were scanned by confocal microscopy. Doxoru-
bicin accumulates in the nuclei, but also in punctate-patterned
organelles, which co-localise with lysosomes (Fig. 7a). A
lysosomal sequestration of doxorubicin represents a possible
clearance mechanism of RD cells. However, no changes were
observed in lysosomal doxorubicin fluorescence intensity or
lysosomal radius (Fig. 7b, c).
The nucleus is the primary target organelle for doxorubicin.
The anthracycline binds to DNA and inhibits topoisomerase II,
which results in blockade of DNA replication and transcription
(Larsen et al. 2000). Consequently, one can postulate that
cytotoxicity of doxorubicin depends on the concentration in
the nucleus. Under control conditions, doxorubicin accumu-
lates readily in the nuclei (Fig. 8). Upon treatment with sim-
vastatin or verapamil for 18 h, the nuclear doxorubicin
fluorescence increased significantly (Fig. 8b). As a weak base,
doxorubicin is sequestered in acidic compartments such as
lysosomes as already shown in Fig. 7a. This sequestration is
thought to represent one mechanism of multidrug resistance
Fig. 5 Simvastatin inhibits ABC transporter-mediated calcein efflux in
RD cells. RD cells were incubated in the absence (ctl) or presence of
3 μM simvastatin (sim) 20 min prior to 1 μM calcein-AM exposure
(a). The fluorescence (excitation 485 nm, emission 535 nm) was
monitored over time until a plateau was reached. Calcein efflux was
visualised by quenching extracellular calcein by the addition of 1 mM
CoCl2. The symbols and bars represent the mean ± SEM (n=6). The
calcein efflux was fitted to bi-exponential decays and the half lives are
depicted from applications with 1 (1 sim) or 10 (10 sim) μM simva-
statin or 15 μM verapamil (15 ver) (b, c). The bars and errors represent
the mean ± SD (n=8)
b
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that may exist separately from the ABC transporters (Schindler
et al. 1996). Treatment of the cells with concanamycin A, an
inhibitor of the lysosomal proton pump, destroys these organ-
elles and still leads to accumulation and nuclear deposition of
doxorubicin (Fig. 7a, b). Importantly, 50 nM concanamycin A
is below the concentration range which has been described to
interfere with ABCB1 function (0.1–10 μM) (Sharom et al.
1995).
To analyse the kinetics of nuclear doxorubicin uptake,
time series were taken from doxorubicin-exposed cells using
confocal microscopy. Simvastatin immediately accelerated
the nuclear compartmentalisations of doxorubicin, which
was not prevented by co-incubation with mevalonic acid
(Fig. 8c). This is of utmost importance and indicates that
an HMG-CoA reductase-independent mechanism is respon-
sible for the nuclear doxorubicin accumulation, which is
already observed within 1 h of co-administration.
Enhanced topoisomerase II inhibition and DNA
double-strand breaks by simvastatin plus doxorubicin
Simvastatin-induced inhibition of ABCB1 results in enhanced
nuclear deposition of doxorubicin. Therefore, nuclear extracts
from RD cells were probed for decatenation of kinetoplast DNA.
This assay is specific for topoisomerase II activity, the target
enzyme of anthracyclines. Expectedly, the topoisomerase II activ-
ity is inhibited to a greater extent by the drug combination of
simvastatin plus doxorubicin (Fig. 9a, b). Complementary, topo-
isomerase II inhibition may result in less DNA repair and this
should facilitate the detection of DNAdouble-strand breaks. Thus,
the increment in histoneH2AXphosphorylation on serine139was
used as a sensitive measure for DNA double-strand breaks
(Watters et al. 2009). Again, a combination of simvastatin and
doxorubicin significantly enhanced DNA injury compared to the
individual compounds alone (Fig. 9c, d). Interestingly, simvastatin
alone or in a combination with mevalonic acid failed to increase
DNA double-strand breaks. This indicates that the induction of
apoptosis by simvastatin alone has not reached DNA
laddering within the experimental time frame of 18 h. More-
over, these findings corroborate the initial hypotheses that
simvastatin-induced nuclear compartmentalisation of doxoru-
bicin significantly enhances efficacy of the anthracycline.
Discussion
Statins, like simvastatin, are used for the treatment of
hypercholesterolaemia and prevention of cardiovascular
Fig. 6 Down-regulation of
ABCB1 by simvastatin. The
presence of ABCB1 was
confirmed by Western blot
analysis in untreated and
simvastatin-treated (sim) RD
cells, incubated for 48 h (a).
Protein loading is controlled
with α-tubulin. The intensity of
the 140- and 170-kDa ABCB1
protein band was corrected for
protein loading and the
normalised intensities are
depicted as mean ± SD (n=3) in
b. The asterisk denotes
statistical significance versus
control (*p<0.05). Similar to
the experiments depicted in
Fig. 5, calcein efflux was
determined in RD cells after
48 h of incubation with 3 and
30 μM simvastatin (sim) versus
control (ctl). Simvastatin was
removed before calcein-AM
loading. The half lives of the
first (c) and second calcein
release phase (d) were
presented as mean ± SD (n=6)
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events (Corsini et al. 1999; Group 2000; Nielsen et al.
2012). They belong to the most widely prescribed drugs
and are well tolerated, besides occasionally occurring skel-
etal muscle side effects, which are now understood as apo-
ptotic events (Corsini et al. 1999; Sacher et al. 2005). In
recent years, evidence has accumulated that statins also
exert an anti-proliferative activity including cell cycle arrest,
inhibition of angiogenesis, stimulation of anti-tumour
immunity and impairment of metastatic potential
(Sleijfer et al. 2005). In different tumour cell lines, it
was shown that statins induce growth inhibition by
blocking the transition of G1–S phase in the cell cycle
(Lee et al. 1998; Rao et al. 1999; Dimitroulakos et al.
2001; Wachtershauser et al. 2001; Ukomadu and Dutta
2003) and by induction of apoptosis via the mitochon-
drial pathway in human RD cells (Werner et al. 2004),
melanoma cells (Minichsdorfer and Hohenegger 2009),
human lymphocytes, myeloma cells (Cafforio et al. 2005) and
others (Dimitroulakos et al. 2001; Sieczkowski et al.
2010). However, apoptosis is seen in tumour cells only
above 1–3 μM of the individual statins which represent
a more than 10-fold higher concentration compared to
pharmacological statin treatment (Corsini et al. 1999).
This is hampered by co-application of the anthracycline
doxorubicin which is capable to shift the concentration–
response curve for simvastatin to the left by a factor of
10 (Fig. 1a).
In our study, we show that 100 nM doxorubicin is capa-
ble of shifting the EC50 of simvastatin-induced caspase 3
activation from 9.9 to 0.7 μM. This anthracycline concen-
tration is found in the plasma of tumour patients treated with
doxorubicin (Giaccone et al. 1997; Swenson et al. 2003). In
contrast, the peak plasma concentrations reached in patients
after oral simvastatin administration are approximately
0.14 μM (Lennernas and Fager 1997). Thus, induction of
apoptosis with an EC50 of 0.7 μM simvastatin is clearly
above this value. However, we speculate that lower doses of
these drugs may also be effective in prolonged incubations,
since the apoptotic effects of statins are time and dose
dependent (Werner et al. 2004; Minichsdorfer and
Hohenegger 2009). Indeed, low-dose statins given continu-
ously seem to exhibit some anti-tumour activity (Sleijfer et
al. 2005; Nielsen et al. 2012), which might explain the
Fig. 7 Doxorubicin is sequestered into lysosomes of RD cells. RD
cells were incubated with 1 μM doxorubicin (Dox) and simulta-
neously with 20 nM Lysotracker® Red (Lyso) for 1 h (a). Cells
were supplied with fresh medium and pictures were taken with a
confocal laser microscope. The intensity of the lysosomal pattern
outside the nuclear region was analysed for lysosomal radius and
mean lysosomal fluorescence intensity in the absence (ctl) and
presence of 10 μM simvastatin (sim) or 15 μM verapamil (ver)
(b, c) after a drug exposure of 1 h. The bars represent the mean ± SD
(n=91–296; n.s. not significant)
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protective effect observed in case–control studies (Boudreau et
al. 2004; Graaf et al. 2004; Poynter et al. 2005) and in a study
performed in hepatocellular carcinoma (Kawata et al. 2001).
The latter observation is of particular interest because the
concentrations which statins might reach in the liver are signif-
icantly higher than those in the serum. The liver–plasma ratio of
10:2 after subcutaneous application of atorvastatin, simvastatin,
lovastatin or pravastatin confirms this assumption (Chen et al.
2007). Importantly, liver injury is a rare statin side effect
and often linked to concomitant drug administration or
pre-existing liver diseases (Corsini et al. 1999).
Although doxorubicin represents a hallmark in many
anti-cancer drug regimens, its role in children soft tissue
sarcoma has been controversially discussed (Bisogno et al.
2005). However, our in vitro results are indicative of a
rational with a potential role of statins as an emerging
candidate for combinatory chemotherapy. Synergistic inter-
actions between statins and various cytotoxic drugs were
found in vitro and in vivo: (1) simvastatin was found to act
synergistically with carmustine in vitro and in vivo (Soma et
al. 1995). (2) Lovastatin potentiated the anti-tumour effects
of cisplatin in MmB16 melanoma cells (Feleszko et al.
1998), of 5-fluorouracil and cisplatin in colon cancer cells
(Agarwal et al. 1999), of doxorubicin in Colon-26 cells, v-
Ha-ras-transformed NIH-3T3 sarcoma cells and Lewis lung
carcinoma cells in vitro and in vivo (Feleszko et al. 2000).
(3) Cerivastatin synergistically enhanced cytotoxicity of 5-
fluorouracil in colorectal cancer cells (Wang et al. 2002) and
of doxorubicin and cisplatin in human breast cancer cells
(Kozar et al. 2004). Interestingly, with the exception of
doxorubicin and in part carmustine, these chemotherapeu-
tics are no substrates for ABCB1 (Szakacs et al. 2006).
Cisplatin is a substrate for ABCC2, ABCC5 and ABCC6
and the thiopurine 5-fluorouracil for ABCC5 and ABCC11
(for review, see Szakacs et al. 2006). Accordingly, statins
may impact also other ABC transporters, which has been
confirmed for ABCC1 and ABCC2 (Wang et al. 2001;
Sakaeda et al. 2002; Chen et al. 2005). One should have in
Fig. 8 Enhanced nuclear deposition of doxorubicin by simvastatin,
verapamil or concanamycin A treatment. RD cells were grown on glass
cover slides and incubated for 18 h in the absence (ctl) or presence of
10 μM simvastatin (sim), 15 μM verapamil (ver) or 50 nM
concanamycin A (con) for 1 h. Such treated cells were subsequently
exposed to 1 μM doxorubicin for an additional hour (a). Representa-
tive experiments are depicted and the bar indicates 10 μm. The inten-
sity of the nuclear doxorubicin accumulation is blotted for the
conditions described under a (b). The bars represent the mean ± SD
(n=55–69 cells). To resolve the kinetics of the nuclear doxorubicin
accumulation, RD cells were preincubated for 20 min in the absence
(filled circles) or presence of 10 μM simvastatin (open triangle) or a
combination of 10 μM simvastatin plus 1 mM mevalonic acid (filled
square) (c). The experiment was started by the addition of doxorubicin
(1 μM) and pictures were taken every 2 min. Images were analysed
with Metafluor® imaging software. The symbols represent the mean ±
SEM (n=14–38)
b
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mind that CYP3A4 substrates in many cases share also sub-
strate specificity for ABCB1 (Gottesman et al. 2002; Szakacs
et al. 2006). However, in the clinics, side effects due to in-
teractions via ABC transporters are not described for statins
(Corsini et al. 1999; Szakacs et al. 2006; Tamaki et al. 2011),
although a polymorphism in the gene of the organic anion-
transporting polypeptide (OATP1B1) has been attributable for
elevated statin plasma levels and increased risk for
myotoxicity (Link et al. 2008). Given the fact that tumour
cells replicate faster than normal tissue, one can speculate that
statins might have a greater impact on the expression of ABC
transporters in tumour cells compared to normal cells.
In RD cells, simvastatin induced nuclear accumulation of
doxorubicin, which is not related to inhibition of HMG-CoA
reductase (Fig. 8). Thus, one has to postulate a novel drug
target for simvastatin. In accordance with previous findings
(Bogman et al. 2001; Wang et al. 2001; Sakaeda et al. 2002;
Sieczkowski et al. 2010), we confirm that simvastatin is a
potent inhibitor of ABCB1. This is corroborated by the
following findings: (1) verapamil, a prototypical first genera-
tion ABCB1 inhibitor, also led to enhanced nuclear accumu-
lation of doxorubicin. (2) Doxorubicin is a substrate of
ABCB1 and confers doxorubicin resistance which is therefore
of clinical relevance (Endicott and Ling 1989; Gottesman et
al. 2002; Szakacs et al. 2006). Moreover, ABCB1 is expressed
in RD cells and calcein efflux is inhibited by simvastatin
(Fig. 6a). (3) Simvastatin is also efficient in another cellular
system. In CCRFvcr1000 cells which stably express a defined
number of ABCB1 transporters, daunorubicin and rhoda-
mine123 fluxes were inhibited by simvastatin. (4) An alterna-
tive explanation might be provided by our recent observations
on the glycosylation level of ABCB1 in the presence of
simvastatin in human neuroblastoma cells (Sieczkowski et
al. 2010). Simvastatin reduced the 170-kDa fully glycosylated
species and thereby might impair the plasma membrane ex-
port of the transporter. A similar down-regulation is observed
in RD cells upon simvastatin exposure times up to 48 h
(Fig. 6a, b). Western blot analyses confirm a strong decline
Fig. 9 Enhanced topoisomerase II inhibition and DNA double-strand
breaks by co-application of simvastatin with doxorubicin. Topoisom-
erase II activity from nuclear extracts (20 μg) of RD cells is depicted in
the absence (ctl) or presence of 0.1 μM doxorubicin (dox), 1 mM
mevalonic acid (ma), 1 μM simvastatin (sim) or the combination of
0.1 μM doxorubicin with 1 mM mevalonic acid or 1 μM simvastatin
(a). The standards for catenated kinetoplast DNA (kDNA) and
decatenated (decat.) kDNA are indicated. Quantification of catenated
and mini-circles kDNA is given in b (bars represent mean ± SD, n=5).
Asterisks indicate statistical significance versus control determined
with ANOVA and post hoc Dunnett’s test (*p<0.05; ***p<0.001).
In order to detect DNA double-strand breaks, RD cells were exposed to
0.1 μM doxorubicin (dox), 1 mM mevalonic acid (ma), 1 μM simva-
statin (sim), 10 μM etoposide (etop) or the combination of doxorubicin
with simvastatin or simvastatin plus mevalonic acid for 18 h. Thereaf-
ter, the cells were probed for histone H2AX phosphorylation by FACS
analysis and a normalised histogram is shown (c). Quantification of
histone H2AX phosphorylation is summarised in d (mean ± SD, n=3–
8). Indicated statistical significance was determined with ANOVA and
post hoc Tukey’s test
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of the 170-kDa ABCB1 band, but also of the 140-kDa core-
glycosylated species.
Interestingly, the lactone forms of statins are more potent to
inhibit P-glycoprotein, compared to their corresponding acid
forms (Bogman et al. 2001). For comparison, lovastatin in the
acid form with the open lactone ring exerts a greater potency in
pro-apoptotic action in cancer cell lines (Dimitroulakos et al.
2001). Pravastatin already exists in its acidic form and cannot
inhibit ABCB1 (Bogman et al. 2001; Wang et al. 2001).
Indirectly, these results imply that HMG-CoA reductase inhi-
bition is not a prerequisite for ABCB1 inhibition. This is
supported by our finding that the enhanced nuclear accumula-
tion of doxorubicin is not abrogated by the co-application of a
saturating concentration of mevalonic acid (Fig. 8c). Thus,
ABCB1 and other ABC transporters like ABCC1 and ABCC2
are confirmed to be new targets for statins (Bogman et al. 2001;
Wang et al. 2001; Chen et al. 2005; Sieczkowski et al. 2010).
Besides the efflux mechanism of ABC transporter, cellular
drug clearance may also involve sequestration to acidic com-
partments such as lysosomes, recycling endosomes, the trans-
Golgi network or secretory vesicles (Schindler et al. 1996;
Larsen et al. 2000). Indeed, a punctuated staining of doxorubicin
was detected in RD cells, which was attributed to lysosomes. In
contrast to nuclear deposition, simvastatin did not modulate the
sequestration of the weak base doxorubicin to this acidic com-
partment (Figs. 7 and 8). Conversely, destruction of lysosomes
by the V-type ATPase inhibitor concanamycin A resulted in a
significant elevation of nuclear doxorubicin (Fig. 7b). Remark-
ably, this finding highlights the importance of the lysosomal
drug clearancemachinery of tumour cells. Concanamycin Awas
also found to inhibit ABCB1, although in a concentration range
between 0.1 and 10 μM (Sharom et al. 1995). Thus, in our
experimental settings, 50 nM concanamycin A is assumed to
have no effect on the ABC transporter.
Nevertheless, the combination of simvastatin and doxo-
rubicin shows a significant increment in topoisomerase II
inhibition and DNA double-strand breaks (Fig. 9). Impor-
tantly, incubation with simvastatin alone had no effect on
topoisomerase II activity or the occurrence of DNA double-
strand breaks. This is again indicative for a synergistic
action of the two drugs and highlights the importance of
doxorubicin guidance into the nucleus by simvastatin.
Taken together, these data lead to the conclusion that
simvastatin enhances the nuclear deposition of doxorubicin
by direct inhibition of ABCB1 and on long term by down-
regulation of the transporter. Consequently, this effect trans-
lates into further inhibition of topoisomerase II and enhanced
DNA double-strand breaks. Interestingly, ABCB1 expression
assessed by immunohistochemistry was an adverse prognostic
factor in paediatric rhabdomyosarcoma patients (Chan et al.
1990). It remains to be elucidated whether statins can partially
overcome chemotherapy resistance in vivo, prevent relapses
and improve the overall outcome in rhabdomyosarcoma.
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